Elosulfase Alfa (Vimizim®)

Vimizim (elosulfase alfa) is covered only for confirmed mucopolysaccharidosis type IVA (Morquio A) and is excluded for all other indications. Approval requires diagnostic confirmation by deficient N‑acetylgalactosamine‑6‑sulfatase activity in leukocytes or fibroblasts OR molecular genetic testing showing the GALNS mutation, prescription by or consultation with a geneticist/endocrinologist/metabolic disorder or lysosomal storage disorder specialist, is authorized for 12 months, and must be dosed 2 mg/kg IV weekly (infused over ~3.5–4.5 hours).

"Vimizim (elosulfase alfa) is indicated for the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)."

Sign up to see full coverage criteria, indications, and limitations.